AZ's R&D information chief eyes improved trial success

AstraZeneca ($AZN) has plenty to learn from clinical trials that ended in failure, and the company has turned to many different new computer technologies to streamline its R&D efforts and boost efficiency in drug development. In a wide-ranging interview with Bio-IT World, John Reynders, head of R&D information, commented on the solutions on the table to increase the chances of triumphing in mid- and late-stage clinical trials. "We're also looking at translational informatics, segmentation analytics, biomarker platforms, how can we bring to bear all that insight into patient populations," he said. Q&A

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.